Previous studies have shown that next-generation sequencing analyses represent robust and efficient methods for the detection of BRCA1/2 alterations from FFPE tumor tissue, including ovarian cancer specimen [10,11,12]. This evidence concerns the gene BRCA1 and ovarian cancer.